ClinicalTrials.gg
RecruitingNCT05280405EPICUpdated Aug 18, 2023

Early Proactive Therapeutic Drug Monitoring of Infliximab in Children: EPIC Study

A Phase 4 interventional study of Infliximab in Inflammatory Bowel Diseases, sponsored by IRCCS Burlo Garofolo. Recruiting at 1 site in Italy. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2023-08-18.

Sponsored by IRCCS Burlo Garofolo · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2024, 2 years 9 months ago, but the record still lists the study as recruiting.
  • Started Mar 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies testing infliximab in Inflammatory Bowel Diseases — 6 open to participants now, 7 under way, none of them phase 3. Infliximab · Inflammatory Bowel Diseases.

Planned enrollment
10th of 20
86 · median 83
Started
2022
with 2 others
Phase 4
10 of 20
4 open now
Registered
14th of 20
by date
Lead sponsor
1 of 20
IRCCS Burlo Garofolo

Among the 20 studies testing infliximab in Inflammatory Bowel Diseases, this one is the 10th largest by planned enrollment, is one of 3 that started in 2022, is one of 10 in phase 4, and was the 14th registered.

Inflammatory Bowel Diseases

1,555 studies on the registry are indexed under Inflammatory Bowel Diseases; 425 are open to participants now.

Browse Inflammatory Bowel Diseases studies →

Open to participants now

6 of the 20 studies testing infliximab in Inflammatory Bowel Diseases are open now, in 6 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

About infliximab

Infliximab: first FDA approval 1998 (REMICADE), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 276 Inflammatory Bowel Diseases studies recruiting now, 134 (49%) set no upper age limit and 114 (41%) stop at 75 or younger; 75 take children under 18; 60 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing infliximab in Inflammatory Bowel Diseases, or all of them as a file.
02

Study summary

The purpose of the study is to assess whether a proactive therapeutic drug monitoring strategy, introduced early during treatment, improves Infliximab (IFX) durability, efficacy and safety in children and young adults with inflammatory bowel disease. Patients with an indication to receive IFX, based on current clinical practice recommendations, will receive the drug either based on IFX concentrations determined before every IFX infusion, starting from the third infusion, or at standard dosing. Approximately 90 patients will be included in this research study. Patients enrolled will be in the study for approximately 12 months.

Read the detailed description

Inflammatory Bowel Disease (IBD) are relapsing disorders with progressive bowel damage leading to long-term disability.

Infliximab (IFX), is a highly effective and commonly used biologic in IBD. However, up to 40% of patients do not respond to treatment or lose response over time. Low-serum IFX concentrations and the development of antibodies to IFX (ATI) are two major factors affecting IFX efficacy, durability and safety. Standard IFX dose is administered as an IV (in the vein) infusion at 5 mg/kg in a 0, 2, and 6 weeks induction regimen followed by a maintenance regimen with infusions every 8 weeks. This standard dosing is extrapolated from adult studies. IFX has a highly variable pharmacokinetic and pharmacodynamics that is dependent on body weight, disease extent, levels of inflammation and the presence of ATI. In children and young adults with IBD all these factors often result in low-serum IFX concentrations.

Proactive therapeutic drug monitoring, consists in the measurement of drug concentrations on patient's blood, in order to adjust the following administrations (dosing or interval) and maintain a desired concentration of the medication in the body.

This study seeks to determine whether a proactive therapeutic drug monitoring strategy can improve IFX durability, efficacy and safety in children and young adults with IBD. The study will involve approximately 90 patients, aged 6 to 17 years, with IBD. All the patients enrolled in the study will receive IFX at 5mg/kg at week 0, 2 and 6. At week 6 patients will be randomly assigned to receive IFX treatment either based on IFX concentrations determined before every IFX infusion (intervention group) or at standard dosing (control group). Patients will participate in the study for 54 weeks (approximately 12 months) or until IFX discontinuation. During the study, patients will visit the study center at the time of every IFX infusion or in case of disease flares.

03

Conditions studied

  • Inflammatory Bowel Diseases

Keywords

  • Infliximab
  • Proactive drug monitoring
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Anti-TNF naïve children and adolescents, 6-17 years, with a diagnosis of IBD confirmed by a prior endoscopic that is consistent with the diagnosis
  2. Indication to start anti-TNF therapy in accordance with current pediatric guidelines for the treatment of pediatric IBD
  3. Active inflammation supported by CRP > 5mg/L and /or FC > 150 μg/g before the 1st IFX dose

Exclusion criteria

Exclusion Criteria:

  1. Consent withdrawal,
  2. Stenosing or penetrating disease requiring surgery, abdominal abscess, symptomatic stricture,
  3. Abdominal surgery within the previous 6 months,
  4. Acute severe ulcerative colitis attack defined by a PUCAI score Ñ 65,
  5. Infective to IFX treatment including positive tuberculin skin test or Quantiferon-TB test, recent opportunistic infection, infection with (HBV), C (), (HIV),
  6. Previous exposure to anti-TNF;
  7. Exposure to concomitant prohibited medications including other biologics (including but not limited to ustekinumab, vedolizumab, abatacept, anakinra..), thalidomide, drugs
  8. Pregnancy or lactation
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
86 participants (estimated)

Study arms

  • Experimental
    Early-Proactive Therapeutic Drug Monitoring (E-pTDM)

    Infliximab (IFX) at 5mg/kg, IV at week 0, 2 and 6. From week 6, the infusion interval will be adjusted based on pre-infusion IFX concentrations to target a trough level grater or equal to (\>=) 5 mcg/ml (\> 10 μg/ml in patients with perianal disease). For IFX concentrations below target, the infusion interval will be shortened (minimum interval 2 weeks). IFX dose increase will be performed as a second step.

    Drug: Infliximab

  • Active comparator
    Standard dosing

    Infliximab (IFX) at 5mg/kg, IV at week 0, 2 and 6 followed by 5mg/kg infusions every 8 weeks.

    Drug: Infliximab

Interventions

06

What researchers measure

Primary outcomes

  1. Frequency of IFX discontinuation or need for treatment intensification due to non-response or LOR during the first year of treatment.

    Composite outcome. Treatment intensification is defined as adjunction of rescue therapies, including corticosteroids systemic or topical, azathioprine (AZA), methotrexate (MTX), 5-aminosalicylate (5-ASA) systemic or topical, or rescue IFX escalation or surgery; treatment response is defined as a decrease in Pediatric Crohn's Disease Activity Index (PCDAI) by 12.5 point or in Pediatric Ulcerative Colitis Activity Index (PUCAI) by 10 points with decrease in C reactive protein (CRP) by 50% after induction, evaluated between 12-14 weeks; loss of response (LOR) is defined as PCDAI \>= 10 or PUCAI \> 10 with CRP \> 0.5mg/dl and/or fecal calprotectin (FC) \>250 microg/g in a patient who previously responded to induction treatment.

    Time frame: 54 weeks

Secondary outcomes

  1. Cumulative probability of IFX discontinuation

    Time to IFX discontinuation

    Time frame: 54 weeks

  2. Cumulative probability of Loss of Response

    Time to Loss of Response (LOR), with LOR defined as PCDAI \>= 10 or PUCAI \> 10 with CRP \> 0.5 mg/dl and/or FC \>250 microg/g in a patient who previously responded to induction treatment.

    Time frame: 54 weeks

  3. Frequency of subtherapeutic IFX concentrations

    Subtherapeutic IFX concentration is defined as IFX concentration at trough \< 5 microg/ml (or \<10 microg/ml in perianal CD) during maintenance treatment.

    Time frame: 54 weeks

  4. Frequency of Anti-Infliximab Antibodies

    Evaluation of Anti-Infliximab Antibodies

    Time frame: 54 weeks

  5. Frequency of infusion reactions

    Infusion reactions are defined as reactions that develop during the course of the infusion or within 1-2h of its completion.

    Time frame: 54 weeks

  6. Frequency of endoscopic remission

    Endoscopic remission is defined in patients with Crohn's Disease as a Simple Endoscopic score for Crohn's Disease (SES-CD score) less than or equal to (\<=) 2 and in patients with Ulcerative Colitis as a Mayo sub-score \<= 1

    Time frame: 54 weeks

  7. Frequency of patients with treatment response at the end of induction between 12 and 14 weeks

    Treatment response is defined as a decrease in PCDAI by 12.5 point or in PUCAI by 10 points with decrease in CRP by 50% compared to baseline

    Time frame: Week 14

  8. Frequency of patients with clinical remission at 14 weeks

    Clinical remission is defined as PCDAI \<10 or PUCAI \<10

    Time frame: Week 14

  9. Frequency of clinical and biochemical remission at week 14

    Clinical and Biochemical remission is defined as PCDAI \<10 or PUCAI \<10 with CRP \< 0.5 mg/dl and FC \< 250 microg/g

    Time frame: Week 14

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Jan 2024, 22 months after the start.

Of 33 non-industry phase 4 interventional studies under Inflammatory Bowel Diseases, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 63. This study's planned 22 months is below that.

Counting every sponsor, half of 38 studies reached it within 38 months; a quarter within 21 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2022
First posted
Mar 15, 2022
StartActual
Mar 9, 2022
Primary completionEst.
Jan 31, 2024
CompletionEst.
Jan 31, 2025
Last update
Aug 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05280405
Lead sponsor
IRCCS Burlo Garofolo
Responsible party
Sponsor
First posted
Mar 15, 2022
Start date
Mar 9, 2022
Primary completion
Jan 31, 2024 (estimated)
Completion
Jan 31, 2025 (estimated)
Last update
Aug 18, 2023

Study contacts

Sara Lega, MD PhD
Contact
sara.lega@burlo.trieste.it
+390403785380
Sara Lega
Contact
sara.lega@burlo.trieste.it
+390403785380

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Infliximab

Start the discussion